Frontlight ResearchEarly access
Myeloproliferative neoplasms trials in Germany
21 of 27 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in GermanyA Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Where
- Aachen, Cottbus, Dresden, Erlangen, Essen, Hamburg, Hanover, Jena, Mannheim, Minden
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00 - Phase 1Taking peopleStudy of INCA036978 in Participants With Myeloproliferative Neoplasms
- Where
- Aachen, Berlin, Freiburg im Breisgau, Halle, Mainz
- Age
- 18 years and over
- People
- 218 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07441694 · EU 2026-525217-31-00 - Phase 3Not yet taking people in GermanyA Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- Where
- Aachen, Berlin, Dresden, Freiburg im Breisgau, Halle, Hamburg, Hanover, Homburg, Jena, Lübeck, Mannheim, Minden
- Age
- 18 years and over
- People
- 426 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00 - Phase 4Taking peopleAsciminib Roll-over Study
- Where
- Aachen, Augsburg, Bad Saarow, Berlin, Bonn, Chemnitz, Dresden, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mannheim, Marburg, Muenchen, Munich, Regensburg, Ulm, Wuerzburg
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 3Not yet taking people in GermanyA Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Where
- Berlin, Chemnitz, Freiburg im Breisgau, Halle (Saale), Jena, Koblenz, Minden, Mutlangen
- Age
- 18 years and over
- People
- 324 worldwide
- Run by
- Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00 - Phase 1Taking peopleA Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
- Where
- Aachen, Berlin, Essen, Hanover, Heidelberg, Regensburg
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06150157 · EU 2023-505584-36-00 - Phase 2Active, not recruitingStudy of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- Where
- Essen, Jena, Luebeck, Mannheim, Munich
- Age
- 18 years and over
- People
- 68 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06517875 · EU 2024-518225-15-00 - Phase 3Not yet taking people in GermanyINTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
- Where
- Deggendorf, Dresden, Frankfurt, Greifswald, Halle, Hamburg, Heidelberg, Jena, Mannheim, Mutlangen, Rostock
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07429266 · EU 2025-524669-25-00 - Phase 1/2Taking peopleA Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Where
- Halle (Saale), Luebeck
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00 - Phase 2Active, not recruitingA Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
- Where
- Duesseldorf, Jena
- Age
- 18 years and over
- People
- 38 worldwide
- Run by
- Karyopharm Therapeutics Inc.
See details and how to join2024-511309-47-00 - Phase 2Active, not recruiting(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Aachen, Freiburg im Breisgau, Lübeck, Mannheim
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - Phase 3Taking peopleAdding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
- Where
- Dresden, Duesseldorf, Freiburg im Breisgau, Halle (Saale), Hamburg, Hanover, Heidelberg, Jena, Kiel, Leipzig, Munich, Mutlangen, Nuremberg, Stuttgart, Ulm
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Kartos Therapeutics Inc.
See details and how to join2023-504724-25-00 - Phase 1/2Taking peopleA Study of BGB-11417 in Participants With Myeloid Malignancies
- Where
- Leipzig, Ulm
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00 - No phaseNot yet taking people in GermanyExercise Training in Patients With Myeloproliferative Neoplasms
- Where
- Hanover
- Age
- 18 years and over
- People
- 80
- Run by
- Hannover Medical School
See details and how to joinNCT07384039 - Phase 1Not yet taking people in GermanyA Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Where
- Dresden, Halle, Mainz
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07008118 - Phase 3CompletedA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Berlin, Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz, München
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Phase 3Active, not recruitingStudy on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
- Where
- Dresden
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Italfarmaco
See details and how to joinNCT06093672 · EU 2022-502276-23-00 - Phase 2Taking peopleA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Where
- Düsseldorf, Jena
- Age
- 18 years and over
- People
- 58 worldwide
- Run by
- Karyopharm Therapeutics Inc
See details and how to joinNCT05980806 - Phase 3Taking peopleStudy of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Where
- Düsseldorf, Freiburg im Breisgau, Halle, Hamburg, Hanover, Heidelberg, Jena, Kiel, Leipzig, Munich, Mutlangen, Nuremberg, Stuttgart, Ulm
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT06479135 - Phase 1/2Taking peopleTasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition
- Where
- Aachen
- Age
- 18 years and over
- People
- 20 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06605586 · EU 2024-511565-11-00 - Phase 1/2Taking peopleStudy of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- Where
- Düsseldorf, Halle
- Age
- 18 years and over
- People
- 70 worldwide
- Run by
- Telios Pharma, Inc.
See details and how to joinNCT05280509